Cambrex (NYSE:CBM) is scheduled to post its quarterly earnings results before the market opens on Wednesday, February 13th. Analysts expect Cambrex to post earnings of $1.32 per share for the quarter.
Cambrex (NYSE:CBM) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.59 by ($0.10). The company had revenue of $104.62 million during the quarter, compared to the consensus estimate of $122.04 million. Cambrex had a net margin of 22.67% and a return on equity of 22.20%. The company’s revenue was down 7.1% on a year-over-year basis. During the same quarter last year, the business earned $0.55 earnings per share. On average, analysts expect Cambrex to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of Cambrex stock traded up $0.52 on Monday, hitting $39.94. The company had a trading volume of 38,675 shares, compared to its average volume of 248,628. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.54 and a quick ratio of 3.41. The stock has a market capitalization of $1.32 billion, a PE ratio of 12.60, a price-to-earnings-growth ratio of 1.33 and a beta of 2.45. Cambrex has a 52 week low of $35.98 and a 52 week high of $69.43.
Several research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Cambrex from a “buy” rating to a “hold” rating in a report on Friday, February 1st. ValuEngine cut shares of Cambrex from a “sell” rating to a “strong sell” rating in a report on Thursday, January 31st. TheStreet cut shares of Cambrex from a “b” rating to a “c+” rating in a report on Monday, December 3rd. Robert W. Baird assumed coverage on shares of Cambrex in a report on Thursday, November 15th. They issued an “outperform” rating for the company. Finally, First Analysis upgraded shares of Cambrex from an “outperform” rating to a “strong-buy” rating and decreased their price objective for the company from $73.00 to $63.00 in a report on Friday, November 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Cambrex presently has a consensus rating of “Buy” and an average target price of $62.50.
ILLEGAL ACTIVITY NOTICE: “Cambrex (CBM) to Release Earnings on Wednesday” was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.thelincolnianonline.com/2019/02/11/cambrex-cbm-to-release-earnings-on-wednesday.html.
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates.
Recommended Story: What is Liquidity?
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.